What's Happening?
The NHS Race and Health Observatory has announced the expansion of genomic testing to include DPYD gene variants found in non-European ancestry groups. This initiative aims to address ethnic health inequalities in cancer care by screening for variants that
affect the breakdown of fluoropyrimidine chemotherapy. The North West Genomic Laboratory Hub began screening for the c.557A>G variant in September 2025, which is prevalent in people of African ancestry. As a result, three patients have received personalized chemotherapy doses, reducing their risk of adverse drug reactions. The Observatory is also testing for a fifth variant at six other genomic hubs, following a systematic review that called for broader screening.
Why It's Important?
This development is significant as it addresses the under-representation of ethnic minority groups in medical research and genomic biobanks. By expanding genomic testing, the NHS aims to improve cancer treatment outcomes for diverse populations, ensuring that medical advances benefit everyone. The initiative aligns with the NHS's ten-year plan to prevent serious adverse drug reactions through genomic testing, potentially reducing health disparities and improving patient safety. It highlights the importance of inclusive research in precision medicine, which can lead to more effective and targeted treatments for all ethnic groups.
What's Next?
The NHS Race and Health Observatory plans to continue expanding genomic testing to include more variants, potentially benefiting a wider range of patients. This initiative may prompt other healthcare systems to adopt similar practices, leading to more inclusive and effective cancer care globally. The Observatory's efforts could also influence policy changes, encouraging more research on genetic variants in diverse populations. As genomic testing becomes more widespread, healthcare providers may need to adapt their practices to incorporate these advancements, ensuring equitable access to personalized medicine.
